Using Synthetic Audiences for Healthcare Market Research

Innovations in healthcare require an insight into the people behind the purchasing and implementation decisions. For any healthtech company, agency, or development team, this means conducting market research and targeting such B2B audiences as physicians, health systems executives, procurement experts, and so forth. But traditional methods of reaching out to these people may prove to be problematic. The need to recruit suitable participants, observe all privacy-related regulations, synchronize schedules, and adhere to healthcare-specific restrictions makes this type of research both time-consuming and costly.

Synthetic audiences provide another way of gathering information. Although such personas cannot replace real-life healthcare professionals, they can serve to get some initial understanding of the buyer's point of view. Teams that want to conduct AI research for healthcare teams can use this approach to gather feedback from synthetic personas before actually recruiting participants. Understanding when synthetic audiences can be helpful and when not that's the main point.

There is a much bigger shift happening behind this change in how healthcare teams gather and interpret information. As artificial intelligence moves from experimentation toward more practical healthcare applications, organizations are increasingly exploring tools that can generate, interpret, summarize, and work with complex information. According to the current Coherent Market Insights (CMI) data, the global Generative AI in Healthcare Market is expected to grow from USD 3.86 billion in 2026 to USD 19.72 billion by 2033, registering a CAGR of 26.2% from 2026 to 2033. This rapid expansion helps explain why AI-generated personas and synthetic audiences are becoming relevant to healthcare market research: they are part of a broader movement toward using generative AI to make information-heavy healthcare processes faster and more adaptable.

For research teams, the opportunity is not simply about replacing traditional research with AI. It is about using AI to get closer to the right questions before investing time and resources in finding the people who can ultimately answer them.

Why Healthcare Buyer Research Is Difficult

Business-to-business healthcare research faces its unique practical issues. In such a situation, a company could be looking for opinions about its technologies from hospital administrators, clinicians, IT executives, or procurement managers. Each of those roles could come with different needs, work processes, budgets, and standards for evaluating a technology.

Finding the right people is only the first hurdle. Healthcare professionals as well as decision-makers already have demanding schedules, while research involving sensitive environments may require additional approvals. Privacy and regulatory considerations can further complicate how information is collected, shared, or analyzed.

At the same time, the healthcare technology landscape is becoming increasingly sophisticated. Three developments are particularly relevant to the rise of generative AI-assisted research.

First, healthcare organizations are moving from AI experimentation toward practical workflow applications. Generative AI is increasingly being considered for clinical workflows, documentation, administrative automation, patient engagement, and other day-to-day activities rather than remaining a purely experimental technology. Current industry research shows that healthcare leaders are increasingly focused on implementation, integration, and measurable value.

Second, AI is becoming increasingly important across pharmaceutical research and drug development. Generative models can support activities ranging from scientific research and molecular design to the organization and interpretation of complex information. This is helping push generative AI beyond general-purpose productivity and toward highly specialized healthcare use cases.

Third, the conversation is shifting toward AI that can work with increasingly complex healthcare information while remaining subject to human oversight. Organizations are looking at how AI can support decision-making without turning simulated or machine-generated outputs into unquestioned evidence. That distinction is especially important for synthetic audiences, where the goal is to generate useful early hypotheses rather than pretend that an AI persona is equivalent to a real physician, patient, or healthcare executive.

These developments help explain why synthetic audiences are becoming interesting to healthcare market researchers. As generative AI becomes better at understanding context and producing human-like responses, it can give research teams a faster environment in which to explore questions before moving into human validation.

What Synthetic Audiences Actually Do

Synthetic audiences involve the use of AI-generated personas that help create a simulation of conversation with a defined set of audience profiles. This is done in order to create a space where teams can test their assumptions and find potential patterns before putting effort and money into product or campaign development.

In the case of healthcare B2B teams, this could mean exploring how a hypothetical health system decision-maker might respond to a value proposition or how a clinician persona might react to different forms of messaging.

For teams using synthetic audiences, that means generative AI software can provide an initial environment for exploring how different healthcare stakeholders might respond before those assumptions are taken to real participants. The research questions may include:

• Which benefits will attract attention?
• What objections would be raised by the buyer?
• What terms and claims might confuse the audience?
• How do different audience profiles respond to different positioning?
• Which ideas for the landing page or ads require further exploration?

That is why synthetic research can be especially useful at early stages of decision making. It does not turn simulated responses into market evidence; rather, it gives healthcare teams a faster way to identify assumptions, refine research questions, and decide what needs to be validated through human research.

Testing Messaging Before Launch

A concrete example is marketing language testing. The healthtech firm may have multiple ways to position its product: minimizing the administrative burden, enhancing workflow visibility, reducing operational costs, or simplifying team-to-team communication. Each message may appeal to a different buyer depending on how the technology is used and what problem it is expected to solve.

This is particularly relevant as generative AI moves into a growing range of healthcare applications. A company developing AI for drug discovery and development may need to speak differently to pharmaceutical researchers and biotechnology teams than a company offering AI for clinical and diagnostic support would to healthcare providers. Similarly, solutions focused on medical documentation, administrative automation, or patient engagement may involve different users, purchasing priorities, and expectations. Among these applications, drug discovery and development is projected to account for 31.8% of the global Generative AI in Healthcare Market share in 2026, reflecting the growing use of generative AI in complex healthcare and life sciences workflows.

That diversity makes messaging harder to get right. Instead of selecting a single positioning based purely on internal opinions, teams can use synthetic buyer personas to explore how different stakeholder profiles might respond to different messages. A pharmaceutical buyer may prioritize research efficiency, while a healthcare provider may be more concerned with workflow integration or implementation. Testing these perspectives early can help teams identify which benefits deserve greater emphasis and which assumptions need further validation.

The same approach can be applied to headlines, advertisements, value propositions, landing pages, and other campaign elements. Synthetic feedback cannot predict how the entire healthcare market will respond, but it can help researchers identify weak assumptions and refine their messaging before investing in larger campaigns or human research.

The value, then, is not simply in generating more marketing variations. It is in understanding how the intended audience may interpret them and deciding which reactions are important enough to take forward into real-world research.

Supporting ICP and Positioning Decisions

Synthetic audiences are another tool that can help to define the ideal customer profile. Healthtech startups often have many target audiences but lack the capacity to research them all.

A team can generate personas for each B2B stakeholder group and evaluate how they react to a certain product idea. This can identify interesting research questions for humans down the line. It is especially helpful when there are many buyers for the product. Sometimes the user and the person making the purchasing decision can be two separate people, who have very different pain points.

Prior to diving into the human research, teams can perform synthetic research to answer the following questions:

• Different buyers' priorities and pain points.
• Objections to the product or the service itself.
• The difference between the users and purchasers.
• Certain messaging that may appeal to certain stakeholder groups.
• Interesting questions that need further validation via human interviews.

The range of potential buyers is also expanding as generative AI finds applications across pharmaceutical and biotechnology companies, healthcare providers, healthcare payers, research and academic institutions, and other healthcare organizations. Pharmaceutical and biotechnology companies are projected to hold 38.6% of the global Generative AI in Healthcare Market share in 2026, making them an especially important end-user group. For a research team, that means an AI-enabled product may need to be positioned very differently depending on whether the target audience is a pharmaceutical R&D team, a hospital executive, a healthcare payer, or an academic researcher.

That difference is exactly where synthetic audiences can be useful. They can help teams explore several buyer perspectives before deciding which ones deserve deeper human research.

What Synthetic Research Cannot Do

Healthcare is one example of an industry where the limitations of synthetic audiences need to be explicitly highlighted. Synthetic personas do not make up for actual clinicians, health-system executives, patients, and other stakeholders in the healthcare industry.

They are not able to validate clinical effectiveness, predict patient outcomes, or replace clinical research. They are also unable to ensure that the generated simulated audience mirrors the diversity of the actual healthcare professionals and purchasing organizations.

Synthetic research should thus be confined to relevant buyer-related issues, such as messaging, positioning, product concepts, and early decisions. This research should not be used as validation of clinical safety, medical efficacy, or population behavior.

The issue of representativeness is another key limitation that needs to be considered. The fact that a synthetic persona has been developed for a particular profile means nothing.

Combining AI With Human Research

The best way to employ synthetic audiences would be to use them alongside human research rather than to substitute it. The team could run an AI simulation, which will help it define the focus, possible counterarguments, and initial ideas that would have to be further compared.

The findings that seem the most crucial may then be tested via human interviews with the buyers of healthcare.

In this case, the whole process of research will become more concentrated, as the team will start each project with some assumptions that require validation.

A Faster Research Loop

The value of synthetic audiences becomes clearest when research teams need to explore several buyer perspectives quickly. In healthcare, where a single AI-enabled product may involve clinicians, researchers, administrators, procurement teams, or executives, waiting weeks to test every assumption can slow down early-stage decisions. This is where platforms built around rapid synthetic research can help turn a lengthy research process into a faster first step.

Such platforms like Articos are built on the principles of this type of fast research process. Based on the given information, Articos enables agencies, SaaS teams, product marketers, and startups to model their audience and get results in a structured way in less than 30 minutes, instead of waiting for weeks before getting them through regular research.

The method is called peer-reviewed and scientifically verified in terms of 86% human accuracy in 46 studies, benchmarked against the Baymard Institute and Nielsen Norman Group. For healthcare teams, however, the value of such research is not in treating it as definite proof of the market. Its primary purpose is to speed up the decision-making process at the very beginning, helping teams identify potential reactions and determine where further research should focus.

That need for an efficient first step becomes particularly relevant in the U.S. generative AI healthcare market, where hospitals, health systems, pharmaceutical companies, medical technology firms, insurers, and healthtech startups can have very different purchasing requirements and expectations around AI. The U.S. also represents an important environment for generative AI adoption as healthcare organizations increasingly explore AI for clinical support, documentation, research, administrative workflows, and personalized care.

For companies conducting U.S. healthcare market research, synthetic audiences can therefore provide an early way to explore how different stakeholders may perceive an AI-enabled product. A pharmaceutical R&D executive may focus on research efficiency, while a hospital administrator may be more concerned with workflow integration, implementation, and cost. Testing those perspectives early can help researchers determine where human interviews should focus.

As investment in generative AI continues to expand across healthcare and life sciences, the U.S. is becoming an increasingly important environment for AI-assisted approaches to healthcare market research. The role of synthetic audiences is therefore not to replace real-world research, but to help teams enter that research stage with sharper questions and better-defined assumptions.

Keeping the Methodology Honest

Healthcare market research requires a fine line to be drawn between simulation and evidence. Simulated audiences may assist in testing buyer reaction and developing more effective questions for future human research. They do not replace the necessity of human validation in those cases where a decision needs to be made based on stakeholder behavior, clinical evidence, or population research.

A team using synthetic research methods must set up limits on what information can be used in making decisions. The following steps should be included in a reasonable process:

• Define the research question as one about B2B buyer-side.
• Treat the findings as guidance, not evidence.
• Validate important findings by human participants.
• Avoid using simulations as proof of effectiveness or results for patients.
• Critically evaluate simulated audiences for possible gaps.

The importance of that discipline is reinforced by the growing number of companies developing generative AI capabilities for healthcare and life sciences. Microsoft Corporation, Google LLC, NVIDIA Corporation, Amazon Web Services (AWS), Oracle Corporation, Tempus AI, Inc., Abridge AI, Inc., Hippocratic AI, Aidoc, and Insilico Medicine are among the companies contributing to the broader generative AI in healthcare landscape through AI infrastructure, healthcare applications, clinical support, documentation, and drug discovery technologies.

This approach will help a team to make use of AI-assisted research while understanding its limitations. The technology may make the research loop faster, but the credibility of the final conclusion still depends on how carefully those AI-generated insights are tested.

Conclusion

Artificial audiences have come into play as a valuable approach for market research within the healthcare sector, especially on the B2B buyer side where the research team will need to gain an understanding of the clinician and health system decision maker, among others, before moving forward with the product and campaign. The key strength of artificial audience research is the speed at which this can be done, with the research team able to gain insights around position, message, product, and objection before putting any effort into recruitment or development.

The key to credibility, though, is to know its limitations. Synthetic audiences can help healthcare teams ask better questions sooner; they should not be mistaken for the people who ultimately need to answer them.